Summary: Recent trials have provided us with a lot of key information in the field of pharmacotherapy, which is reflected in the new document of the ESC for the management of heart failure. The new guidelines represent a significant step forward in the treatment of HFrEF. They organize our knowledge of the therapy by defining basic groups of crucial drugs with prognostic significance ‒ β-blockers, MRA, ARNI/ACE-I and SGLT2 inhibitors. Each patient diagnosed with HFrEF should receive the crucial drugs, unless there are specific contraindications. It is worth noting that SGLT2 inhibitors should also be included in patients without coexisting diabetes. Similar principles of management may be considered in patients with HFmrEF, considering loop diuretics as adjuvants, relieving symptoms, but without a documented effect on the long-term prognosis. Unfortunately, further studies are still needed to formulate recommendations for the management of HFpEF and to propose a therapeutic regimen that reduces mortality. This summary synthetically presents the most important principles of the ambulatory management of chronic heart failure by a family physician.